We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+10.71%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.54B
AUM Growth
+$321M
Cap. Flow
-$140M
Cap. Flow %
-5.5%
Top 10 Hldgs %
33.9%
Holding
112
New
21
Increased
26
Reduced
21
Closed
14

Top Buys

Rank Stock Value
1
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$105M
2
DBVT
DBV Technologies
DBVT
+$41.9M
3
LCI
Lannett Company, Inc.
LCI
+$30.8M
4
RVNC
Revance Therapeutics, Inc.
RVNC
+$28.7M
5
ELV icon
Elevance Health
ELV
+$27.7M

Top Sells

Rank Stock Value
1
AVXS
AveXis, Inc. Common Stock
AVXS
+$79.5M
2
MCK icon
McKesson
MCK
+$49.5M
3
NXTM
NxStage Medical Inc.
NXTM
+$43.6M
4
VTRS icon
Viatris
VTRS
+$24.8M
5
PDCO
Patterson Companies, Inc.
PDCO
+$21.9M

Sector Composition

Rank Sector Weight
1 Healthcare 78.77%
2 Financials 0.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BPMC
26
DELISTED
Blueprint Medicines
BPMC
$29.9M 1.18%
396,000
+193,000
+95% +$13.6M
ELV icon
27
Elevance Health
ELV
$80.9B
$29.3M 1.15%
+130,000
New +$27.7M
AERI
28
DELISTED
Aerie Pharmaceuticals
AERI
$28.9M 1.14%
484,055
-148,631
-23% -$9.01M
NTRA icon
29
Natera
NTRA
$38.9B
$26.3M 1.03%
2,920,856
+739,314
+34% +$7.99M
XLRN
30
DELISTED
Acceleron Pharma
XLRN
$26.1M 1.03%
615,000
– –
ACHC icon
31
Acadia Healthcare
ACHC
$3.17B
$24.2M 0.95%
+741,016
New +$25.7M
EVHC
32
DELISTED
Envision Healthcare Holdings Inc
EVHC
$23.4M 0.92%
+676,000
New +$23.6M
ARGX icon
33
argenx
ARGX
$53.8B
$23.1M 0.91%
365,961
-143,061
-28% -$4.68M
IMMU
34
DELISTED
Immunomedics Inc
IMMU
$21M 0.83%
1,300,448
+718,448
+123% +$8.48M
OXFD
35
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$17.7M 0.7%
1,264,000
+318,290
+34% +$4.66M
EHTH icon
36
eHealth
EHTH
$47.3M
$17.6M 0.69%
1,013,916
+340,922
+51% +$7.63M
SCTL
37
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$17.6M 0.69%
2,120,379
– –
RYTM icon
38
Rhythm Pharmaceuticals
RYTM
$7.31B
$16.9M 0.67%
+582,010
New +$15.4M
AAC
39
DELISTED
AAC Holdings
AAC
$16.9M 0.66%
1,873,276
+140,000
+8% +$1.26M
ARDX icon
40
Ardelyx
ARDX
$1.28B
$16.3M 0.64%
2,469,580
-276,900
-10% -$1.64M
CTMX icon
41
CytomX Therapeutics
CTMX
$788M
$15.9M 0.63%
753,322
-3,500
-0.5% -$72.6K
NVTA
42
DELISTED
Invitae Corporation
NVTA
$15.6M 0.62%
1,723,000
+823,000
+91% +$7.38M
AGIO icon
43
Agios Pharmaceuticals
AGIO
$2.36B
$15M 0.59%
262,984
+54,984
+26% +$3.46M
UHS icon
44
Universal Health Services
UHS
$9.15B
$15M 0.59%
+132,000
New +$14.1M
PTLA
45
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$14.5M 0.57%
298,545
– –
BLUE
46
DELISTED
bluebird bio
BLUE
$14.2M 0.56%
+6,176
New +$12.5M
LOXO
47
DELISTED
Loxo Oncology, Inc
LOXO
$14.2M 0.56%
169,000
– –
EPZM
48
DELISTED
Epizyme, Inc
EPZM
$12.7M 0.5%
1,009,526
+309,000
+44% +$4.49M
SYRS
49
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$12.3M 0.49%
126,895
– –
LKFT
50
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.97B
$12.2M 0.48%
130,000
– –
1
2
3 4

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q4 2017 Portfolio in Review

As of Q4 2017, Deerfield Management held 112 positions worth $2.54B, up 14% from $2.22B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Deerfield Management withdrew a net $140M in Q4 2017, closing 14 positions and reducing 21 holdings. Its most notable exit was NxStage Medical Inc., an estimated $43.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 76% a quarter earlier, followed by Financials.

Against the trend, Deerfield Management opened a new position in Revance Therapeutics, Inc. worth $35.8M.

  • Deerfield Management's largest Q4 2017 buy was Revance Therapeutics, Inc.: 1,000,000 shares worth $35.8M.
  • Deerfield Management added most to MALLINCKRODT PUBLIC LIMITED COMPANY in Q4 2017, an estimated $105M increase.
  • Deerfield Management's biggest Q4 2017 reduction was AveXis, Inc. Common Stock, cutting an estimated $79.5M.
  • Deerfield Management fully exited NxStage Medical Inc. in Q4 2017, selling an estimated $43.6M.
  • Deerfield Management's ten largest holdings make up 34% of its $2.54B portfolio in Q4 2017.
  • Deerfield Management opened 21 new positions and closed 14 in Q4 2017.
  • Deerfield Management's portfolio value rose 14% quarter-over-quarter to $2.54B.

Based on Deerfield Management's 13F filing for Q4 2017, filed 14 Feb 2018.